The company had posted a net profit of Rs 71.77 crore for the corresponding period of the previous fiscal, Ipca Laboratories said in a filing to the BSE.
Standalone total income from operations of the company rose to Rs 935.96 crore for the quarter under consideration from Rs 805.56 crore for the same period a year ago.
Total revenue from the formulations business rose to Rs 680.92 crore for the quarter ended June 30, 2014, as against Rs 583.11 crore for the corresponding period of the previous fiscal, Ipca Laboratories said.
Shares of Ipca Laboratories were today trading at Rs 712.90 per scrip in the afternoon trade on the BSE, down 0.45 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%